Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults.

@article{Karp2014SafetyTA,
  title={Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults.},
  author={Jordan Friedman Karp and Meryl A. Butters and Amy E. Begley and Mark D. Miller and Eric J. Lenze and Daniel M Blumberger and Benoit H. Mulsant and Charles F. Reynolds},
  journal={The Journal of clinical psychiatry},
  year={2014},
  volume={75 8},
  pages={e785-93}
}
OBJECTIVE To describe the clinical effect and safety of low-dose buprenorphine, a κ-opioid receptor antagonist, for treatment-resistant depression (TRD) in midlife and older adults. METHOD In an 8-week open-label study, buprenorphine was prescribed for 15 adults aged 50 years or older with TRD, diagnosed with the Structured Clinical Interview for DSM-IV, between June 2010 and June 2011. The titrated dose of buprenorphine ranged from 0.2-1.6 mg/d. We assessed clinical change in depression… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 42 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Similar Papers

Loading similar papers…